Clinical Trial Update: Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 trial of Rezpegaldesleukin (NKTR-358) for new-onset Type 1 diabetes mellitus. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Rezpegaldesleukin (NKTR-358) (rezpegaldesleukin)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: RECRUITING